Provider-Level Barriers to Human Papillomavirus Vaccination in Survivors of Childhood and Young Adult Cancers-Reference-Cited by-同舟云学术

Provider-Level Barriers to Human Papillomavirus Vaccination in Survivors of Childhood and Young Adult Cancers

Published:2021-08-17 Issue: Volume: Page:
ISSN:2156-5333
Container-title:Journal of Adolescent and Young Adult Oncology
language:en
Short-container-title:Journal of Adolescent and Young Adult Oncology

Author:

Kacew Alec J.¹^ORCID,Jacobson Sofia²,Sheade Jori²,Patel Anand A.²,Hlubocky Fay J.²,Lee Nita K.³,Henderson Tara O.⁴,Schneider John A.⁵⁶⁷,Strohbehn Garth W.²⁸⁹^ORCID

Affiliation:

1. Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA.

2. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.

3. Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois, USA.

4. Section of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, University of Chicago, Chicago, Illinois, USA.

5. Section of Infectious Diseases, Department of Medicine, University of Chicago, Chicago, Illinois, USA.

6. Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.

7. Chicago Center for HIV Elimination, University of Chicago, Chicago, Illinois, USA.

8. Veterans Affairs Ann Arbor Medical Center, Center for Clinical Management and Research, Ann Arbor, Michigan, USA.

9. Rogel Comprehensive Cancer Center, University of Michigan Medicine, Ann Arbor, Michigan, USA.

Publisher

Mary Ann Liebert Inc

Subject

Oncology,Pediatrics, Perinatology and Child Health

Link

https://www.liebertpub.com/doi/pdf/10.1089/jayao.2021.0096

Reference31 articles.

1. 1. Centers for Disease Control and Prevention. Cancers Associated with Human Papillomavirus, United States—2013–2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020;USCS Data Brief.

2. Human Papillomavirus-Associated Subsequent Malignancies among Long-Term Survivors of Pediatric and Young Adult Cancers

3. Gender inequalities in cancer among young adults

4. 4. American Cancer Society. Cancer Facts & Figures 2020. Atlanta: American Cancer Society; 2020.

5. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Papillomavirus Vaccination in Pediatric, Adolescent, and Young Adult Cancer Survivors—Opportunity to Address Gaps in Cancer Prevention and Survivorship;Vaccines;2024-01-24

2. Identifying Barriers to HPV Vaccination for Patients With Sickle Cell Disease and Childhood Cancer Survivors;Journal of Pediatric Hematology/Oncology;2023-09-08

3. Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration;Human Vaccines & Immunotherapeutics;2023-06-23

4. Examining the Barriers and Opportunities for Human Papillomavirus Vaccine Delivery in Cancer Care Settings: A Mixed-Methods Study;Cancer Prevention Research;2023-05-31

5. Reasons for refusal of the human papillomavirus vaccine among young cancer survivors;Cancer;2022-12-19